Prolight Diagnostics publishes investorletter for March 2026

About this update from Prolight Diagnostics Ab

The investor letter highlights that Prolight has entered the year with several important milestones that further strengthen the position of our POC platform, Psyros™. Particularly encouraging is the progress in our ongoing funded collaboration with BRAINBox Solutions, where we have achieved highly positive results in an analytical evaluation of three biomarkers for Traumatic Brain Injury (TBI).Read more about this exciting development in the attached document or on the company’s website:https://prolightdx.com/en/mediaeng/investor-letters/For further information, please contact:Ulf Bladin, CEOE-mail:Phone: +46 73 582 39 87Company website:www.prolightdx.comAbout UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.Attachments

View stock analysis, news, and events for Prolight Diagnostics Ab